EpCAM在前列腺癌中的表达及其相关临床意义(5)
[18] Went P,Vasei M,Bubendorf L,et al.Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers[J].British Journal of Cancer,2006,94(1):128.
[19] Long M D, Smiraglia D J,Campbell M J.The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer[J].Biomolecules,2017,7(1):15.
[20] Poczatek R B,Myers R B,Manne U,et al.Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J].J Urol,1999,162(4):1462-1466.
[21] Zellweger T,Ninck C,Bloch M,et al.Expression patterns of potential therapeutic targets in prostate cancer[J].International Journal of Cancer,2005,113(4):619-628.
[22] Tayama S,Motohara T,Narantuya D,et al.The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer[J].Oncotarget,2017,8(27):44312-44325.
[23] Zheng X,Fan X,Fu B,et al.EpCAM inhibition sensitizes chemoresistant leukemia to immune surveillance[J].Cancer Research,2017,77(2):482.
(收稿日期:2019-03-25) (本文編辑:周亚杰), 百拇医药(张继君 张桂平 韩小璐 刘薇薇 陶丽丽)
[19] Long M D, Smiraglia D J,Campbell M J.The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer[J].Biomolecules,2017,7(1):15.
[20] Poczatek R B,Myers R B,Manne U,et al.Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J].J Urol,1999,162(4):1462-1466.
[21] Zellweger T,Ninck C,Bloch M,et al.Expression patterns of potential therapeutic targets in prostate cancer[J].International Journal of Cancer,2005,113(4):619-628.
[22] Tayama S,Motohara T,Narantuya D,et al.The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer[J].Oncotarget,2017,8(27):44312-44325.
[23] Zheng X,Fan X,Fu B,et al.EpCAM inhibition sensitizes chemoresistant leukemia to immune surveillance[J].Cancer Research,2017,77(2):482.
(收稿日期:2019-03-25) (本文編辑:周亚杰), 百拇医药(张继君 张桂平 韩小璐 刘薇薇 陶丽丽)